If you have **mild to moderate** Alzheimer’s disease, you may qualify to take part in a research study that is testing an investigational (not approved by the Food and Drug Administration) drug called bapineuzumab. Bapineuzumab is an antibody against amyloid-β protein, which is thought to cause Alzheimer’s disease. The drug helps remove this protein from the body. Patients will receive bapineuzumab or a placebo (an inactive substance with no medical value). Patients will be allowed to continue taking their current Alzheimer’s disease medications during this study, but will not be allowed to start new medications. Bapineuzumab is given into a vein (IV). This study lasts for about 18 months.

In order to qualify, you must:

- Be 50 to 88 years of age
- Be stable for 3 months on any Alzheimer’s drugs you are taking
- Have no history of cancer for 5 years
- Have no history of heart attack or of autoimmune diseases such as lupus or Crohn’s disease
- Live with someone who is your caregiver and is willing to bring you to the study visits and provide information about your condition

The following will be provided:

- Study medication, study visits and travel expenses

If you are interested, or you know of someone else who might be interested, please call the Providence Cognitive Assessment Clinic at 503-216-1090 and ask about the bapineuzumab study.